Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tigris Pharmaceuticals
This is a randomized, open-label study. Patients will be randomized in a 1:1 ratio to single arm AFP464, or AFP464+Faslodex. Patients will be treated until disease progression is noted.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
proven breast cancer, ER+ status; progression on an aromatase inhibitor; measurable disease or evaluable disease with serum CA27.29\>=50 U/mL; adequate bone marrow, liver and renal function; DLco grade 0 or 1.
You may not be if
HER2 positive, thoracic radiotherapy or symptomatic pulmonary disease, brain metastases,
Clareo Health | Study of AFP464 +/- Faslodex in ER + Breast Cancer
